|
NEURL1B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
3.45799999967866E-07 |
| Normal-vs-Stage3 |
6.11970474295731E-11 |
| Normal-vs-Stage4 |
3.74319999996153E-06 |
| Stage1-vs-Stage2 |
6.092000E-01 |
| Stage1-vs-Stage3 |
9.877000E-01 |
| Stage1-vs-Stage4 |
5.497000E-01 |
| Stage2-vs-Stage3 |
6.503000E-01 |
| Stage2-vs-Stage4 |
8.817000E-01 |
| Stage3-vs-Stage4 |
5.741800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
7.61290000000914E-05 |
| Normal-vs-Asian |
1.10040000000922E-07 |
| Caucasian-vs-AfricanAmerican |
7.268400E-01 |
| Caucasian-vs-Asian |
1.592210E-01 |
| AfricanAmerican-vs-Asian |
1.891020E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.48769885299771E-14 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
2.674600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.55351295663786E-15 |
| Normal-vs-Age(41-60Yrs) |
8.21565038222616E-14 |
| Normal-vs-Age(61-80Yrs) |
3.17820003647995E-09 |
| Normal-vs-Age(81-100Yrs) |
4.638300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.506810E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.688800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.418400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.935200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.589850E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.920400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.612600E-01 |
| Classical-VS-Follicular |
9.790600E-04 |
| Classical-VS-Other |
2.507200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
4.735000E-01 |
| Tall-VS-Other |
5.489200E-01 |
| Tall-VS-Normal |
2.000800E-04 |
| Follicular-VS-Other |
7.496000E-01 |
| Follicular-VS-Normal |
4.07879999775318E-08 |
| Other-VS-Normal |
1.175420E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62825308791525E-12 |
| Normal-vs-N1 |
1.025580E-04 |
| N0-vs-N1 |
9.738200E-01 |
|
|
